The coronavirus (COVID-19) vaccine developed by Pfizer-BioNTech is likely to be just as effective against a highly transmissible mutant strain of the virus that was discovered in the U.K., according to a study by the two companies.

The variant, known as B.1.1.7., was estimated to have first emerged in the U.K. in September. It has an unusually high number of mutations and is associated with more efficient and rapid transmission.

Earlier this month, Dr. Ugur Sahin, co-founder and CEO of BioNTech, told CNBC that the German pharmaceutical company was confident its vaccine would develop an immune response against B.1.1.7.

Sahin said the vaccine also should prove to be effective against a variant discovered in South Africa — another highly transmissible mutation that has raised concerns.

This article was originally written by Sam Meredith for CNBC on January 20, 2021:
http://cnb.cx/2YUGGsR

FIND the model and photographer created this video on Pexels:
https://bit.ly/3aqnKYj

SUBSCRIBE to our channel:
http://bit.ly/3pOwYUZ